文献速递白血病

面板纠错型二代测序对比流式细胞术检测急性髓系白血病可测量残留病

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
PubMed 文献 · Leukemia · 2021-02-08

该研究纳入201例接受常规治疗的成人AML患者,在诱导结束和巩固结束时用纠错型NGS和流式细胞术检测MRD。NGS-MRD阳性患者复发累积发生率更高、总生存和无复发生存更差,且NGS-MRD可补充FCM-MRD的预后信息。

要点

  • 诱导结束时NGS-MRD阳性率约71%,巩固结束时40.9%(中位VAF 0.76%)。
  • NGS-MRD阳性提示更高复发风险和更差生存,在中等细胞遗传学风险中 predictive。
  • NGS-MRD与FCM-MRD联合可最大化临床效用。

核心结论

  • NGS-MRD是一种广泛适用、可扩展且临床信息丰富的MRD检测方法,与FCM-MRD具有协同作用。

研究设计与样本

  • 纳入201例接受常规治疗的成人AML患者,均在形态学缓解期,在诱导结束(PI)和巩固结束(PC)时评估MRD。
  • 使用敏感纠错型二代测序(NGS-MRD)和多参数流式细胞术(FCM-MRD)检测MRD。

主要发现

  • 诱导结束时NGS-MRD阳性率近71%,巩固结束时40.9%(中位VAF 0.76%)。
  • NGS-MRD阳性患者复发累积发生率显著更高(p=0.003),总生存更差(p=0.001),无复发生存更差(p<0.001)。
  • NGS-MRD可预测中等细胞遗传学风险患者的不良结局,并在有利细胞遗传学风险AML中显示潜力。
  • 诱导结束时NGS-MRD阴性患者生存显著优于后续转为NGS-MRD阴性的患者,表明NGS-MRD清除动力学至关重要。
  • NGS-MRD识别了PI时流式细胞术识别病例的80%以上,而FCM识别了NGS识别病例的49.3%;仅少数病例为NGS-MRD阴性但FCM-MRD阳性。

临床怎么用

  • 可结合FCM和NGS-MRD两种方法以最大化临床效用。
  • NGS-MRD可用于常规治疗AML患者的MRD评估和复发风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We accrued 201 patients of adult AML treated with conventional therapy, in morphological remission, and evaluated MRD using sensitive error-corrected next generation sequencing (NGS-MRD) and multiparameter flow cytometry (FCM-MRD) at the end of induction (PI) and consolidation (PC). Nearly 71% of patients were PI NGS-MRD+ and 40.9% PC NGS-MRD+ (median VAF 0.76%). NGS-MRD+ patients had a significantly higher cumulative incidence of relapse (p = 0.003), inferior overall survival (p = 0.001) and relapse free survival (p < 0.001) as compared to NGS-MRD- patients. NGS-MRD was predictive of inferior outcome in intermediate cytogenetic risk and demonstrated potential in favorable cytogenetic risk AML. PI NGS-MRD- patients had a significantly improved survival as compared to patients who became NGS-MRD- subsequently indicating that kinetics of NGS-MRD clearance was of paramount importance. NGS-MRD identified over 80% of cases identified by flow cytometry at PI time point whereas FCM identified 49.3% identified by NGS. Only a fraction of cases were NGS-MRD- but FCM-MRD+. NGS-MRD provided additional information of the risk of relapse when compared to FCM-MRD. We demonstrate a widely applicable, scalable NGS-MRD approach that is clinically informative and synergistic to FCM-MRD in AML treated with conventional therapies. Maximum clinical utility may be leveraged by combining FCM and NGS-MRD modalities.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Patkar N, Kakirde C, Shaikh AF, et al. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia. 2021. PMID: 33558666. doi:10.1038/s41375-021-01131-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。